PMID- 21256912
OWN - NLM
STAT- MEDLINE
DCOM- 20110701
LR  - 20161125
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 72
IP  - 4
DP  - 2011 Apr
TI  - Butyrophilin-like 2 in pulmonary sarcoidosis: a factor for susceptibility and 
      progression?
PG  - 342-7
LID - 10.1016/j.humimm.2011.01.011 [doi]
AB  - The aims of this study were to assess the association of BTNL2G16071A with the 
      course of pulmonary sarcoidosis and to verify the association with disease 
      predisposition. In addition, the linkage between BTNL2G16071A and certain human 
      leukocyte antigen (HLA)-DRB1/DQB1 types was investigated. In a retrospective 
      case-control study BTNL2G16071A, HLA-DQB1, and HLA-DRB1 were typed in 632 
      sarcoidosis patients. These patients were classified into 304 patients with 
      persistent sarcoidosis and 328 patients with nonpersistent sarcoidosis. The BTNL2 
      16071A variant allele was present significantly more often in patients with 
      persistent disease (92.4%; 281/304) compared with patients demonstrating a 
      nonpersistent course (86.6%; 284/328; odds ratio (OR) = 1.89 with 95% confidence 
      interval (95% CI) 1.11-3.22). Furthermore, BTNL2 16071A variant allele carriers 
      have an increased risk (OR = 1.85, 95% CI 1.19-2.88) of developing sarcoidosis. 
      Moreover, the strong linkage between variant allele and HLA-DRB1*15 presence (OR 
      = 8.43, 95% CI 3.02-23.5) was confirmed. The presence of a BTNL2G16071A variant 
      allele almost doubles the risk of progressing to persistent pulmonary sarcoidosis 
      in addition to increasing the risk of developing sarcoidosis. Presumably, these 
      increased risks are caused by the strong linkage between BTNL2G16071A and 
      DRB1*15. The choice between determining BTNL2G16071A SNP or the HLA-DRB1 type 
      depends on the ability and/or availability to perform either test.
CI  - Copyright (c) 2011 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Wijnen, Petal A
AU  - Wijnen PA
AD  - Department of Clinical Chemistry, Maastricht University Medical Centre, 
      Maastricht, The Netherlands.
FAU - Voorter, Christina E
AU  - Voorter CE
FAU - Nelemans, Patty J
AU  - Nelemans PJ
FAU - Verschakelen, Johny A
AU  - Verschakelen JA
FAU - Bekers, Otto
AU  - Bekers O
FAU - Drent, Marjolein
AU  - Drent M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110120
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (BTNL2 protein, human)
RN  - 0 (Butyrophilins)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Membrane Glycoproteins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - Butyrophilins
MH  - Child
MH  - *Disease Progression
MH  - Female
MH  - Gene Frequency
MH  - *Genetic Predisposition to Disease
MH  - HLA-DR Antigens/immunology
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Male
MH  - Membrane Glycoproteins/*genetics/*immunology
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Sarcoidosis, Pulmonary/*genetics/immunology
MH  - Young Adult
EDAT- 2011/01/25 06:00
MHDA- 2011/07/02 06:00
CRDT- 2011/01/25 06:00
PHST- 2010/10/26 00:00 [received]
PHST- 2010/12/18 00:00 [revised]
PHST- 2011/01/13 00:00 [accepted]
PHST- 2011/01/25 06:00 [entrez]
PHST- 2011/01/25 06:00 [pubmed]
PHST- 2011/07/02 06:00 [medline]
AID - S0198-8859(11)00019-X [pii]
AID - 10.1016/j.humimm.2011.01.011 [doi]
PST - ppublish
SO  - Hum Immunol. 2011 Apr;72(4):342-7. doi: 10.1016/j.humimm.2011.01.011. Epub 2011 
      Jan 20.